机构：[1]Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P. R. China[2]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, P. R. China[3]Department of Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P. R. China[4]Department of Forensic Genetics, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan, P. R. China[5]Department of Obstetrics and Gynecology, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P. R. China[6]Department of Gynecology, Zigong Maternity and Child Health Care Hospital, Zigong, Sichuan, P. R. China[7]Lisen Imprinting Diagnostics Wuxi, Ltd., Wuxi, Jiangsu, P. R. China[8]Lisen Imprinting Diagnostics, Inc., Wilmington, Delaware, USA[9]Department of Gynecology, Chengdu Chenghua District Maternal and Child Health Center, Chengdu, Sichuan, P. R. China[10]Department of Pathology, Nanjing First Hospital, Nanjing, Jiangsu, P. R. China[11]Department of Pathology, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P. R. China[12]Department of Pathology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, P. R. China[13]Department of Pathology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA[14]Department of Pathology, Harbor-UCLA Medical Center, Torrance, California, USA[15]Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, P. R. China[16]Division of Medical Oncology, Mayo Clinic Arizona, Phoenix, Arizona, USA[17]Department of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, P. R. China四川省肿瘤医院[18]Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P. R. China
Cervical cancer remains a significant global public health issue due to its high incidence and mortality. Current clinical guidelines recommend screening for high-risk human papillomavirus (hrHPV)-DNA alongside a Thinprep cytologic test (TCT) before further medical evaluation [1]. The hrHPV-DNA test detects 14 high-risk HPV genotypes including the predominant hrHPV16/18, which can cause cervical abnormalities that may progress to cancer if untreated. TCT is paired with the hrHPV-DNA test to pathologically classify cervical specimens into categories based on increasing malignancy risks. Despite the high sensitivities, both tests have high false positive rates which lead to unnecessary colposcopy while HPV is cleared naturally in most women without progressing into lesions. To reduce overdiagnosis and overtreatment, several DNA methylation detections [2, 3] have been developed for triaging the malignancy risk of hrHPV-positive cervical lesions, but have yet to become clinically available. Here, we proposed an epigenetic biomarker panel based on imprinting alterations as a high-performance triage method to improve cervical cancer risk assessment accuracy in hrHPV-positive women.
基金：
National Natural Science Foundation of China (82071651), Chengdu Science and Technology Bureau (2017-GH02-00030-HZ), National Key Research and Development Program of China
(2022YFC3600304, 2022YFC2704700), Science and Technology Department of Sichuan Province (23ZDYF2489),
Sichuan Province Cadre Health Care Scientific Research
Project (CGY2023-1701) and the Chengdu Technological
Innovation R&D Project (2021-YF05-00595-SN).
第一作者机构：[1]Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P. R. China[2]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, P. R. China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P. R. China[2]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, P. R. China[7]Lisen Imprinting Diagnostics Wuxi, Ltd., Wuxi, Jiangsu, P. R. China[8]Lisen Imprinting Diagnostics, Inc., Wilmington, Delaware, USA[18]Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P. R. China
推荐引用方式(GB/T 7714)：
Xiao Xue,Wang Wei,Bai Peng,et al.Genomic imprinting biomarkers for cervical cancer risk stratification[J].Cancer Communications (London, England).2024,44(12):1385-1390.doi:10.1002/cac2.12617.
APA：
Xiao Xue,Wang Wei,Bai Peng,Chen Ying,Qin Zhengwen...&Liu Hanmin.(2024).Genomic imprinting biomarkers for cervical cancer risk stratification.Cancer Communications (London, England),44,(12)
MLA：
Xiao Xue,et al."Genomic imprinting biomarkers for cervical cancer risk stratification".Cancer Communications (London, England) 44..12(2024):1385-1390
